Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma

Sep 8, 2025Oncology research

Progress in Understanding Liver Cancer Environment and Immune-Based Treatments

AI simplified

Circadian Biology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Hepatocellular carcinoma (HCC) presents significant challenges due to an immunosuppressive tumor microenvironment that may hinder therapy effectiveness.

The tumor microenvironment in HCC is characterized by components such as tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells that contribute to immune escape.
Immunotherapy, particularly immune checkpoint inhibitors, has improved treatment options but often provides limited benefit as a standalone therapy.
Combination strategies targeting multiple immune checkpoints and integrating anti-angiogenic agents could enhance the efficacy of immunotherapy.
The review highlights the interaction between the tumor microenvironment and immune responses, suggesting that combination regimens may help to overcome immune resistance.
Challenges remain, including therapeutic resistance and adverse immune-related effects, which need to be addressed for improved patient outcomes.

AI simplified

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, largely driven by an immunosuppressive tumor microenvironment (TME) that facilitates tumor growth, immune escape, and resistance to therapy. Although immunotherapy-particularly immune checkpoint inhibitors (ICIs)-has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses, their clinical benefit as monotherapy remains suboptimal. This limitation is primarily attributed to immunosuppressive components within the TME, including tumor-associated macrophages, regulatory T cells (Tregs), and myeloid-derived suppressor cells (MDSCs). To address these challenges, combination strategies have been explored, such as dual checkpoint blockade targeting programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), as well as synergistic use of ICIs with anti-angiogenic agents or TME-targeted interventions. These approaches have shown encouraging potential in enhancing immune efficacy. This review outlines the complex crosstalk between the TME and immunotherapeutic responses in HCC, emphasizing how combination regimens may overcome immune resistance. Furthermore, we discuss the remaining hurdles, including therapeutic resistance and immune-related adverse events, and propose future directions involving TME-associated biomarkers and individualized treatment strategies to improve patient outcomes.

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text ↗

Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the circadian biology brief